home

Experts Discuss the Latest Trends in HBV

EVENTShealio2016-04-21 15:30 Read   90

While hepatitis B virus continues to be a major global health problem, incidence in the U.S. has significantly declined since the introduction of the universal vaccine in the 1990s.

Probing Gut Microbiome, Second Genome Nabs $43M To Push Colitis Drug

Frontierxconomy2016-04-21 14:55 Read   77

econd Genome, a South San Francisco, CA-based biotech using microbiome research to develop traditional small-molecule drugs, has tapped an unusual group of private investors for nearly $43 million in a Series B round of financing.

Argos Lays Off 18 and Executive Resigns, But Phase 3 Still on Track

Trendxconomy2016-04-21 14:50 Read   104

Argos Therapeutics has already secured financing expected to carry the company far enough to report late-stage clinical trial results for its experimental kidney cancer treatment, but that hasn’t stopped the company from taking additional cost-cutting measures.

Boehringer Ingelheim charts strong growth in livestock meds ahead of Merial union

EVENTSfiercepharma2016-04-21 14:39 Read   299

Pharma giant Boehringer Ingelheim, which is in the process of merging its Vetmedica unit with Sanofi’s ($SNY) Merial division, reported strong results in animal health for 2015

Catalent plant gets 14 observations from FDA

Regulatorfiercepharma2016-04-21 14:34 Read   101

Miami-based Opko was caught off guard last month when the FDA cited concerns over a Catalent ($CTLT) plant in Florida that is producing its drug candidate as the reason the agency was putting off its decision on whether to approve it.

Biogen CEO sees bonus pay drop on MS, hemophilia trouble

EVENTSfiercepharma2016-04-21 14:28 Read   137

What a difference a year made for Biogen ($BIIB) CEO George Scangos. After reaping a $4 million-plus cash bonus for 2014 performance, Scangos collected $1.2 million for 2015.

FDA lambasts Sri Krishna Pharma plant in new warning letter

CommentsSri Krishna2016-04-21 14:20 Read   78

Data manipulation and integrity issues have struck again as the FDA called out India's Sri Krishna Pharmaceuticals in a newly published warning letter, highlighting several concerns it's noted for years at the drugmaker's operation.

GSK pumping out millions more Ellipta inhalers with new U.K. plant

EVENTSfiercepharma2016-04-21 14:16 Read   92

GlaxoSmithKline CEO Andrew Witty is still counting on new respiratory meds to help pull the company out of the financial doldrums, and he has a new inhaler plant in the U.K. to help meet what he says is growing demand.

Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)

Trenddynavax2016-04-21 14:08 Read   84

Data Presented at NFID's Annual Conference on Vaccine Research

First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trendbms2016-04-21 14:01 Read   94

Bristol-Myers Squibb Company (NYSE: BMY) announced today the first presentation of data from CheckMate -141, a Phase 3 open-label, randomized trial, evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab).

Treato Finds DTC Pharma TV Advertisements Have Little Influence

Commentsprnewswire2016-04-21 13:56 Read   73

Timed to the DTC Perspectives conference kicking off this week, Treato, the single largest source of online consumer insights on healthcare, released their annual survey on consumers' opinions of DTC advertisements.

Pharma digital spending ticks upward slowly but surely

Frontierfiercepharma2016-04-21 13:51 Read   86

Digital spending is expected to overtake TV media spending in the advertising industry this year, but for the pharma industry that’s not nearly true yet. Drug marketers are beginning to shift, however, if only at the slow speed customary in the pharma world.